Business Wire (Free subscription) | 27/08/2008
CHICAGO--(BUSINESS WIRE)--If you like to use a company’s P/E ratio to determine its value, then you’ll love using the PEG
Fool.com (Free subscription) | 21/08/2008
Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer.
Medical News Today (Free subscription) | 21/08/2008
Bristol-Myers Squibb Company (NYSE: BMY) and PDL BioPharma, Inc. (NASDAQ: PDLI) today announced an agreement for the global development and commercialization of PDL BioPharma's anti-CS1 antibody, elotuzumab, previously known as HuLuc63, currently in Phase I development for multiple myeloma.
Seeking Alpha (Free subscription) | 20/08/2008
Eben Tessari submits: Bristol-Myers Squibb (BMY) and PDL BioPharma (PDLI) announced an agreement for the global development and commercialization of PDL BioPharma’s anti-CS1 antibody, elotuzumab (HuLuc63), currently in Phase I development for multiple myeloma. Does someone have some cash burning a hole in their knickers? BMS has been on fire in the last six months divesting non-core assets, buying...
Fiercebiotech (Free subscription) | 20/08/2008
Bristol-Myers Squibb is paying $30 million upfront in a licensing deal for PDL BioPharma's experimental blood cancer vaccine elotuzumab. And will it pay up to $680 million more if the Phase I cancer therapy hits all of its development and sales milestones. The anti-CS1 antibody binds to a protein that plays a key role in multiple myeloma, flagging it for destruction by the human immune system. BMS...
Market Watch (Free subscription) | 20/08/2008
Drug stocks wandered into negative territory early Wednesday while shares of PDL Biopharma gained modestly on news that it has entered into a development agreement with Bristol-Myers Squibb for one of its oncology agents.
Market Wire (Free subscription) | 19/08/2008
REDWOOD CITY, CA (MARKET WIRE) PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) will hold an investor conference call and webcast today at 5:00 p.m. Eastern time following today's announcement of a collaboration agreement with Bristol-Myers Squibb Company for the co-development and commercialization of elotuzumab, PDL's phase 1 antibody candidate for multiple myeloma, and an option, exercisable by Bristol-Myers...
Fool.com (Free subscription) | 18/08/2008
PDL BioPharma and Enzon look to spin off parts of their business.
bizjournals (Free subscription) | 11/08/2008
PDL BioPharma Inc. on Monday reported second quarter net income of $33.9 million, or 24 cents a share, compared to $10.9 million, or 9 cents a share in the same period last year. (PDLI) (DNA)
Market Wire (Free subscription) | 11/08/2008
REDWOOD CITY, CA (MARKET WIRE) PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the quarter ended June 30, 2008. The financial results for continuing operations are summarized below; the complete financial results, including discontinued operations, are included in the financial tables accompanying this press release.
Market Wire - Pharmaceuticals and Biotech (Free subscription) | 17/07/2008
REDWOOD CITY, CA (MARKET WIRE) PDL BioPharma, Inc. (NASDAQ: PDLI) today announced the appointment of Gary A. Lyons to the company's board of directors. The board also elected Mr. Lyons to serve as chairperson of the Compensation Committee, and as a member of the board's Nominating and Governance Committee.
bizjournals (Free subscription) | 27/06/2008
PDL BioPharma Inc. will temporarily pay its outside directors a supplemental $10,000-per-month retainer. (PDLI)
The San Francisco Business Times (Free subscription) | 26/06/2008
PDL BioPharma Inc. will temporarily pay its outside directors a supplemental $10,000-per-month retainer. (PDLI)
Market Watch (Free subscription) | 13/06/2008
Drug stocks climb into positive territory while shares of PDL Biopharma fall following an analyst downgrade.
Market Watch (Free subscription) | 13/06/2008
BOSTON (MarketWatch) -- Drug stocks climbed into positive territory early Friday while shares of PDL Biopharma fell following an analyst downgrade. The Amex Pharmaceutical Index edged up 0.8% to 286.4 and the Amex Biotechnology Index rose 1.1% to 748.4 during a relatively calm morning for the sectors on Wall Street. PDL Biopharma was the notable decliner amongst the large cap biotech companies, down...
